Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-finding study of oral BI 1819479 in idiopathic pulmonary fibrosis (IPF)
jRCT2071240055Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2024
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing BI 1819479 dose groups with Placebo (2 arms). Primary endpoint: Annual rate of decline in FVC. Started Sep 2024; status: active, not recruiting.
02
Drugs
BI1819479
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on jRCT2071240055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071240055.